Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

被引：1
|
作者：
Tanvetyanon, T [1 ]
机构：
[1] Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Inst, Maywood, IL 60153 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 01期
关键词：
D O I：
10.1093/jnci/dji016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [41] Endothelin and skeletal metastases in hormone-refractory prostate cancer
    Hamdy, FC
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 15 - 19
  • [42] Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors
    Coleman, R
    Rosen, L
    Gleason, DM
    Zheng, M
    BONE, 2004, 34 : S84 - S85
  • [43] Hormone-refractory and metastatic prostate cancer - Palliative radiotherapy
    Moser, Lutz
    Schubert, Tina
    Hinkelbein, Wolfgang
    CONTROVERSIES IN THE TREATMENT OF PROSTATE CANCER, 2008, 41 : 117 - 125
  • [44] Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
    Yu, A. P.
    Namjoshi, M.
    Xie, J.
    Parikh, K.
    Wu, E. Q.
    Guo, A.
    Culver, K. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone
    Saad, F
    Gleason, D
    Murray, R
    Venner, P
    Goas, JA
    Chen, BL
    Seaman, J
    JOURNAL OF UROLOGY, 2003, 169 (04): : 394 - 394
  • [46] Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone
    Saad, F
    Gleason, D
    Murray, R
    Fulfaro, F
    Kretzschmar, A
    Yanagihara, R
    Weinfurt, K
    Lacerna, L
    Brandman, J
    CANCER TREATMENT REVIEWS, 2005, 31 : S29 - S29
  • [47] Nanodiamonds enhance therapeutic efficacy of doxorubicin in treating metastatic hormone-refractory prostate cancer
    Salaam, Amanee D.
    Hwang, Patrick T. J.
    Poonawalla, Aliza
    Green, Hadiyah N.
    Jun, Ho-wook
    Dean, Derrick
    NANOTECHNOLOGY, 2014, 25 (42)
  • [48] Chemotherapy for patients with hormone-refractory prostate cancer
    Joly, F
    Tannock, IF
    ANNALS OF ONCOLOGY, 2004, 15 (11) : 1582 - 1584
  • [49] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [50] The role of doxorubicin and epirubicin for the treatment of patients with metastatic hormone-refractory prostate cancer
    Petrioli, Roberto
    Pascucci, Alessandra
    Francini, Edoardo
    Fiaschi, Anna Ida
    Sciandivasci, Angela
    Miano, Salvatora
    Marsili, Stefania
    Francini, Guido
    ANNALS OF ONCOLOGY, 2007, 18 : 74 - 74
12345